Browse by author
Lookup NU author(s): Rebecca Garnham, Dr Daniel Geh, Ryan Nelson, Erik Ramon Gil, Laura WilsonORCiD, Dr Laura Walker, Dr Beth Adamson, Adriana Buskin, Dr Anastasia Hepburn, Dr Kirsty Hodgson, Hannah Kendall, Dr Kelly Coffey, Professor Craig Robson, Professor David Elliott, Professor Rakesh Heer, Dr Jennifer Munkley, Dr Luke GaughanORCiD, Dr Jack LeslieORCiD, Dr Emma ScottORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Immune checkpoint blockade trials have yet to produce a robust anti-cancer response in prostate cancer patients as a monotherapy due to the immunosuppressed prostate cancer tumour immune microenvironment. ST3Gal1 and other sialyltransferases are implicated in cancer and immune suppression by synthesizing sialoglycans, which act as ligands for Siglec receptors. These checkpoints are important for the immune response. However, it's unclear how the synthesis of Siglec ligands is regulated, and little is known about the role of sialoglycan-Siglec-axis in prostate cancer's evasion of anti-tumour immunity. We report that ST3Gal1 levels negatively correlate with androgen signalling in prostate tumours. Utilising syngeneic mouse models, we demonstrate that ST3Gal1 plays an important role in modulating tumour immune evasion. Using mouse models, patient samples and in vitro models we show that ST3Gal1 synthesises sialoglycans with the capacity to engage the Siglec-7 and Siglec-9 immunoreceptors preventing immune clearance of cancer cells. For the first time we provide evidence of the expression of Siglec-7/9 ligands and their respective immunoreceptors in prostate tumours. Importantly, we show that these interactions can be modulated by enzalutamide and may maintain immune suppression in enzalutamide treated tumours. We conclude that the activity of ST3Gal1 is critical to prostate cancer anti-tumour immunity and provide rationale for the use of glyco-immune checkpoint targeting therapies in advanced prostate cancer.
Author(s): Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt EN, Walker L, Adamson B, Buskin A, Hepburn A, Hodgson K, Kendall H, Frame FM, Maitland NM, Coffey K, Robson CN, Elliott DJ, Heer R, Macauley MS, Munkley J, Gaughan L, Leslie J, Scott E
Publication type: Article
Publication status: Published
Journal: bioRxiv
Year: 2023
Print publication date: 04/04/2023
Acceptance date: 04/04/2023
Publisher: Cold Spring Harbor Laboratory
URL: https://doi.org/10.1101/2023.04.03.535346
DOI: 10.1101/2023.04.03.535346
Altmetrics provided by Altmetric